Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

Nimotuzumab:

  • Daiichi Sankyo, CIMYM's licensee for nimotuzumab in Japan, previously initiated a randomized trial with the EGFR-targeting humanized monoclonal antibody in second line gastric cancer together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in Korea, which they report completed recruitment in calendar 2009. Daiichi also launched a Phase II trial in first-line NSCLC for which YM has been advised that recruitment has been completed. Reports on both trials are expected during the first half of calendar 2011 as data mature. Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported safety data from a Phase III trial in adult glioma patients at ASCO 2010 and OSAG continues to recruit patients into a Phase IIb/III trial in pancreatic cancer patients. We are now advised by OSAG that data from the adult glioma trial may be released in the first half of 2011.

  • YM's two randomized, Phase II, double-blind trials of nimotuzumab (for brain metastasis from non-small cell lung cancer and for palliative stage NSCLC) are lagging recruitment targets and consequently these programs are under review as the Company focuses support on the more advanced trials involving Daiichi Sankyo which have the prospect of earlier registration trial initiation. YM's Phase II, second-line, single-arm study in children with progressive diffuse intrinsic pontine glioma (DIPG) has concluded recruitment at multiple sites in the US, Canada, and Israel and should report results prior to the end of calendar 2010.
  • CYT997:

  • Phase I clinical trial results for CYT997 were published in the premier cancer journal, the British Journal of Cancer, demonstrating that CYT997 was well tolerated at doses that were associated with evidence of vascular disruption in tumors. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity currently in a Phase II trial for glioblastoma
    '/>"/>

  • SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
    (Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
    (Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
    (Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
    Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
    ... 22 Edwards Lifesciences,Corporation (NYSE: EW ... of heart valves,today announced the opening of ... North Crescent, Singapore. The state-of-the-art facility produces,Edwards, ... also serves as the headquarters for Edwards, ...
    ... 22 Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: ... product,candidate, CDX-110, being developed for the treatment of ... oral presentation at the 44th,Annual Meeting of the ... will be held at McCormick Place in Chicago ...
    ... to Add Valuable Clinical Development Expertise, SAN ... company focused on the development of novel Toll-Like,Receptor ... respiratory and,autoimmune diseases, announced today the appointment of ... "We are pleased to have Elliott join our ...
    Cached Biology Technology:Edwards Lifesciences Opens New Singapore Heart Valve Facility 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors 2
    (Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
    (Date:8/19/2014)... 19, 2014 To improve students, chances of ... the University of Houston (UH) implemented a comprehensive ... at risk for failure. , Through a ... (THECB), the Department of Biology and Biochemistry embarked ... taking "General Biology" for non-majors and "Introductory Biology" ...
    (Date:8/19/2014)... German . ... If a large amount of electricity is to be produced ... have to be stored during productive periods so that these ... far from adequate for the purpose. Science and industry are ... on battery systems that used to be too expensive or ...
    Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
    ... Boston, MA Using 120 years of feathers ... University researchers have been able to track increases in ... nigripes ), an endangered seabird that forages extensively throughout ... the observed increase in methylmercury levels, most likely from ...
    ... University of the Negev software engineering students have developed ... computer without using a keyboard or mouse only ... to develop devices to read brainwaves and operate specific ... a laboratory setting. The BGU ...
    ... April 18, 2011 Mention vitamin D-fortified foods and ... with the sunshine vitamin since the 1930s. A new ... Challenges/Chemistry Solutions" podcast series says that vitamin D-fortified bread ... essential nutrient that is difficult to get naturally in ...
    Cached Biology News:Mercury on the rise in endangered Pacific seabirds 2
    ...
    RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
    ... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
    ... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
    Biology Products: